Big Buttons

• PCAC to discuss 503A bulks list substances

  FDA’s Pharmacy Compounding Advisory Committee has announced that it will hold two meetings (!) between now and year-end to consider recommending several bulk drug substances to the 503A Bulks List.  read more →

• Next APC regional meeting: Seattle

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Seattle area October 3. read more →

• Don’t skip EduCon’s final (fantastic) session(s)

  The final session of this year’s EduCon is coming up in just a few weeks, and it’s a special double helping of legal goodness. read more →

• Welcome, new PFMs!

  We’ve added 31 Pharmacy-Facility Members since February! read more →

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

More News

Semaglutide, tirzepatide, and more:
Shortage-drug compounding and GLP-1s

• GLP-1 Compounding Primer (2-page PDF)
• APC’s detailed statement on shortage drug compounding and GLP-1s
• Compounded GLP-1 reporting: Our CEO’s commentary
• APC’s statement in response to claims by Eli Lilly (March 2024)